Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Shores Up Gene Therapy Ambitions With New Deal

Executive Summary

Biogen Inc. has furthered its gene therapy ambitions by entering into a broad alliance with the University of Pennsylvania that could see it paying out up to $2bn in research funding and other payments. Biogen has made a series of moves over the past couple of years to build up its gene therapy research.

You may also be interested in...

Biogen Backs Out Of Hemophilia, But Who Benefits?

With no buyers in the hemophilia space and a need to create a more streamlined company, Biogen Inc. announced May 3 that it has done the only thing it can – spin out its hemophilia business. It's still unclear whether this will be a positive strategy for either company.

Gene Therapy's Future Can Be NAV-igated Alone, REGENXBIO CEO Says

Having netted $148m in its September initial public offering, REGENXBIO, Inc. is moving toward the clinic with its first two gene therapy candidates and believes it – and its licensees – are positioned to succeed in gene therapy where earlier attempts failed. Coming out of a "quiet period" after its IPO, which sold 7.2 million shares at $22 apiece, REGENXBIO CEO Kenneth Mills talked to Scrip's sister publication "The Pink Sheet" DAILY about his company's plans and strategies, as well as why its novel adeno-associated virus (NAV) vectors might be more viable than the first iteration of AAV-based therapies.

Sangamo Looks Forward After Shire Returns Hemophilia Rights

Sangamo Biosciences touted the progress of its in vivo protein replacement platform (IVPRP) as it reported that Shire relinquished its rights to hemophilia programs under the companies' three-year-old collaboration, but investors were wary about the loss of an important alliance for two out or four partnered programs as well as the exchange of milestone fees for total control of preclinical assets.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts